Robert M. Wenham, MD, MS, FACOG, FACS
Chair, Department of Gynecologic Oncology
Moffitt Cancer Center
Tampa, Florida

Dr. Robert Wenham is a gynecologic oncologist and Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, a Senior Member of the Chemical Biology and Molecular Therapeutics Program, and Professor of Oncologic Sciences in the Morsani School of Medicine.  He has received the Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation and been awarded a HOW Fellowship for work in ovarian cancer.  He is principal investigator for numerous clinical trials to improve cancer care for women with a focus on novel drugs, immunotherapy, and cellular therapy for the treatment of gynecologic cancers. He serves on advisory committees, steering committees, or data safety committees for clinical studies. He is also an expert in complex abdominopelvic surgeries including exenterative surgery. 

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Authors/Presenters:
Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Content Reviewer: 
Justine Cooper Pickarski, MS, LGC—has no relevant financial relationships to disclose in relation to the content of this activity.
Elizabeth Etkin-Kramer, MD, FACOG—has no relevant financial relationships to disclose in relation to the content of this activity.